Steadman Philippon Research Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1988-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.sprivail.org
Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan
Phase 1
Recruiting
- Conditions
- Knee Arthroplasty, Total
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Steadman Philippon Research Institute
- Target Recruit Count
- 120
- Registration Number
- NCT06108063
- Locations
- 🇺🇸
The Steadman Clinic, Vail, Colorado, United States
Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan
Phase 1
Active, not recruiting
- Conditions
- Femoroacetabular Impingement
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Steadman Philippon Research Institute
- Target Recruit Count
- 68
- Registration Number
- NCT05025956
- Locations
- 🇺🇸
The Steadman Clinic, Vail, Colorado, United States
Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
Phase 1
Active, not recruiting
- Conditions
- Osteoarthritis, Knee
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Steadman Philippon Research Institute
- Target Recruit Count
- 100
- Registration Number
- NCT04815902
- Locations
- 🇺🇸
The Steadman Clinic, Vail, Colorado, United States
Losartan to Improve Hip Microfracture
Phase 1
Terminated
- Conditions
- Hip Impingement SyndromeFibrosisHip OsteoarthritisCartilage Damage
- Interventions
- Other: Placebo
- First Posted Date
- 2019-12-27
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Steadman Philippon Research Institute
- Target Recruit Count
- 1
- Registration Number
- NCT04212650
- Locations
- 🇺🇸
Steadman Philippon Research Institute, Vail, Colorado, United States
Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial
Phase 1
Completed
- Conditions
- Osteoarthritis, Knee
- Interventions
- Dietary Supplement: FisetinDrug: Placebo oral capsule
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Steadman Philippon Research Institute
- Target Recruit Count
- 75
- Registration Number
- NCT04210986
- Locations
- 🇺🇸
The Steadman Clinic, Vail, Colorado, United States
Prospective Evaluation of PRP and BMC Treatment to Accelerate Healing After ACL Reconstruction
Phase 1
Active, not recruiting
- Conditions
- Osteoarthritis, Knee
- Interventions
- Biological: Leukocyte-Poor Platelet Rich Plasma (LP-PRP)Biological: Bone Marrow Concentrate (BMC)Other: Control group (Placebo)
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Steadman Philippon Research Institute
- Target Recruit Count
- 45
- Registration Number
- NCT04205656
- Locations
- 🇺🇸
181 West Meadow Drive, Suite 1000, Vail, Colorado, United States
BFR Therapy After ACL Reconstruction
Not Applicable
Withdrawn
- Conditions
- ACL InjuryQuadriceps Muscle Atrophy
- Interventions
- Device: Sham blood flow restriction therapy - with Delfi Personalized Tourniquet SystemDevice: Blood flow restriction therapy - with Delfi Personalized Tourniquet System
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- Steadman Philippon Research Institute
- Registration Number
- NCT03794570
- Locations
- 🇺🇸
The Steadman Clinic, Vail, Colorado, United States
Dynamic ACL Brace: In Vivo Kinematics
Not Applicable
Withdrawn
- Conditions
- ACLACL - Anterior Cruciate Ligament RuptureACL InjuryACL - Anterior Cruciate Ligament Deficiency
- Interventions
- Device: Ossur Rebound ACL Brace
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Steadman Philippon Research Institute
- Registration Number
- NCT03670550
- Locations
- 🇺🇸
Steadman Philippon Research Institute, Vail, Colorado, United States
© Copyright 2025. All Rights Reserved by MedPath